Inquirer on MSN1d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
Pharm Exec6d
Spravato’s Transformative Impact: Offering Hope and Rapid Relief for Patients with Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
News on 62d
FDA expands approval for antidepressant nasal spray
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
pharmaphorum1d
GH Research leaps on psychedelic data in depression
GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
BioPharma Dive2d
Shares of psychedelics biotech nearly double on depression data
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
BioSpace2d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Imagine Healthcare Announces Expanded Access To Spravato - Now Available Without The Need For An Oral Antidepressant
( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...
Hosted on MSN4d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
'It changed my life tremendously': P.E.I.'s new ketamine clinic could offer mental health help
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...